Superparamagnetic iron oxide nanoparticles in clinical applications: current status and future perspectives
Open Access
- 3 December 2025
- journal article
- review article
- Published by Elsevier in EBioMedicine
- Vol. 122, 106054
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (61821002)
- Jiangsu Province Natural Science Foundation (BK20222002)
- Ministry of Science and Technology of the People's Republic of China
- National Key Research and Development Program of China (2024YFF0508600)
This publication has 107 references indexed in Scilit:
- Exploring Prolonged Efficacy of Ferumoxytol‐Enhanced Whole‐Body MR Angiography: A Preliminary Study in Healthy Male SubjectsJournal of Magnetic Resonance Imaging, 2024
- Multienzyme‐Like Nanozymes: Regulation, Rational Design, and ApplicationAdvanced Materials, 2023
- Deep Penetrating and Sensitive Targeted Magnetic Particle Imaging and Photothermal Therapy of Early‐Stage Glioblastoma Based on a Biomimetic NanoplatformAdvanced Science, 2023
- Off‐resonance artifact correction for MRI: A reviewNMR in Biomedicine, 2022
- Clinical magnetic hyperthermia requires integrated magnetic particle imagingWIREs Nanomedicine and Nanobiotechnology, 2022
- Multicenter clinical trial on sentinel lymph node biopsy using superparamagnetic iron oxide nanoparticles and a novel handheld magnetic probeJournal of Surgical Oncology, 2019
- Comparison of gadolinium‐enhanced and ferumoxytol‐enhanced conventional and UTE‐MRA for the depiction of the pulmonary vasculatureMagnetic Resonance in Medicine, 2019
- Silica‐coated magnetic nanoparticles labeled endothelial progenitor cells alleviate ischemic myocardial injury and improve long‐term cardiac function with magnetic field guidance in rats with myocardial infarctionJournal of Cellular Physiology, 2019
- Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of careJournal of Magnetic Resonance Imaging, 2018
- Staging of rectal cancer by double-contrast MR imaging using the rectally administered superparamagnetic iron oxide contrast agent ferristene and IV gadodiamide injection: Results of a multicenter phase II trialJournal of Magnetic Resonance Imaging, 2000